Amgen Inc. (AMGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Amgen Inc. stock price
Amgen Inc. latest news:
Amgen beats EPS, sales revenue, increases guidance
Shares of Amgen Inc. rose 1% late Wednesday after the biotech drug maker reported third-quarter earnings above Wall Street expectations and increased its guidance for the year. Amgen earned $2 billion, or $2.76 a share, in the quarter, compared with $2 billion, or $2.68 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $3.27 a share, up from $3.02 a share a year ago on higher operating margins. Revenue rose fell 1% to $5.77 billion, compared with $5.81 billion a year ago. Analysts polled by FactSet had expected adjusted earnings of $3.11 a share on sales of $5.75 billion. Amgen said hurricane recovery efforts are "well underway" in its Puerto Rico facility with no expected impact on product supply and an expected 2017 impact of 15 cents to 18 cents a share. Amgen revised its 2017 GAAP EPS guidance to between $10.96 and $11.20 a share, and adjusted EPS guidance to between $12.50 and $12.70. The company upped its revenue guidance to between $22.7 billion to $23 billion. The analysts surveyed by FactSet expected adjusted EPS of $12.58 for the year on sales of $22.9 billion. Amgen shares ended the regular trading day down 1.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amgen quarterly profit tops expectations despite sales decline
(Reuters) - Amgen Inc reported higher-than-expected third quarter profit on Wednesday as lower research and other costs and higher operating margins helped offset sales declines in some of its biggest established products.
BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint
Amgen Inc(AMGN). * Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients. * Amgen Inc(AMGN) - overall safety profile of once-weekly KYPROLIS regimen was comparable to that of twice-weekly regimen Source text for Eikon: Further company coverage:
BRIEF-Amgen and Boston Children's Hospital enter into neuroscience research collaboration
Amgen Inc(AMGN). * Amgen(AMGN) - co, Boston Children's Hospital entered into neuroscience research collaboration aimed at identifying novel pain targets. * Amgen Inc (AMGN) - one-year collaboration will focus on patients with genetic anomalies of pain sensitivity Source text for Eikon: Further company coverage:
What CytomX Gets From Its Huge Amgen Collaboration
CytomX stock rockets 35% after deal with Amgen
CytomX Therapeutics Inc. roared 35% higher in after-hours trading Tuesday to prices that would be record highs after announcing a partnership with biotech giant Amgen Inc. The companies will collaborate on an immuno-oncology product focusing on t-cell therapeutics developed by CytomX, with CytomX leading early development and Amgen taking over for later development and commercialization. Amgen is paying CytomX $40 million and buying $20 million in CytomX stock, and CytomX has the opportunity to earn up to $455 million based on milestones and share in profits from the U.S. while receiving royalties on non-U.S. sales of the drug. Amgen also receives the right to develop and commercialize three undisclosed CytomX candidates, with CytomX eligible to receive $950 million based on the performance of those therapies as well as royalties. CytomX stock topped $25 in late trading, a level it has never cracked in regular trading, after closing at $19. Amgen shares were stable in after-hours action.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
AbbVie and Amgen Reach Global Resolution of Humira
Amgen reaffirms 2017 guidance in wake of Hurricane Maria
Amgen Inc. said early Monday that it does not expect a Hurricane Maria-related interruption to its drug supply and reaffirmed its 2017 guidance. No product or in-process inventory has been lost in the aftermath of the hurricane, which recently hit Puerto Rico, Amgen said, and the company has kept enough inventory to meet patient demand. Hurricane Maria did not "significantly" impact Amgen's key manufacturing areas in its Juncos, Puerto Rico facility, and the company is working to restore its Puerto Rico operations back to normal. Outreach to more than 2,000 Amgen employees and their families is ongoing, the company also said, and the Amgen Foundation has pledged $3 million and up to $2 million more for hurricane relief efforts. Amgen shares were not active in premarket trade. Shares have surged 7.7% over the last three months, compared with a 2.6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
U.S. FDA approves biosimilar version of cancer drug Avastin
Sept 14 (Reuters) - The U.S. Food and Drug Administration
said on Thursday it has approved Amgen Inc's biosimilar
version of Roche Holding AG's cancer drug Avastin.
UK Stocks-Factors to watch on Sept 7
Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10
points higher at 7354.13 on Thursday, according to financial bookmakers.
* RBS: Britain's financial regulator should release a leaked report about
Royal Bank of Scotland that alleged many companies suffered from
"inappropriate action" by its Global Restructuring Group unit, a senior British
* ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma
from AstraZeneca and Amgen promises t
BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® ...
Amgen Inc(AMGN). * FDA accepts Amgen's(AMGN) filing of a supplemental new drug application to add overall survival results to Kyprolis® label. * Amgen Inc (AMGN) - FDA sets PDUFA target action date of April 30, 2018. * Amgen Inc (AMGN) - Adverse events observed in updated analysis were consistent with those previously reported for endeavor Source text for Eikon: Further company coverage:
Is the System Rigged Against Biosimilars?
Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?
Amgen's cholesterol drug is cost-effective at $10,000 a year: study
Amgen Inc.'s cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, according to a new study published in the medical journal JAMA Cardiology. The analysis used data from a trial enrolling patients with established atherosclerotic cardiovascular disease, which can cause a heart attack or stroke, and used rates of those events in a typical population. Repatha's list price is more than $14,500 a year; that price does not reflect often-substantial discounts. Repatha and other cholesterol-controlling PCSK9 drugs -- intended for patients whose cholesterol levels haven't been reduced sufficiently by lifestyle changes or statins -- haven't sold as well as expected, due to, in part, their high price tags. The new JAMA Cardiology study will likely play a role in price negotiations between health insurers, which have been extremely reluctant to cover drugs like Repatha, pharmacy-benefit managers and Amgen. Amgen shares weren't active in postmarket trade. Shares have surged 9.7% over the last three months, compared with a 1.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amicus Therapeutics, Inc.FOLD
Amkor Technology, Inc.AMKR
Amphastar Pharmaceuticals, Inc.AMPH
Amtech Systems, Inc.ASYS
AmTrust Financial Services, Inc.AFSI
Anacor Pharmaceuticals, Inc.ANAC